Trial Profile
HBsAg Loss/Seroconversion in Inactive Chronic Hepatitis B Carriers Treated With Peginterferon Alpha-2a.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Mar 2015
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- 09 Mar 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 18 Nov 2011 New trial record